MindWalk (NASDAQ:HYFT) Announces Earnings Results

MindWalk (NASDAQ:HYFT) posted its earnings results on Monday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04), Zacks reports. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%.

MindWalk Stock Performance

NASDAQ HYFT traded up $0.03 during trading hours on Monday, hitting $1.33. 171,103 shares of the company’s stock traded hands, compared to its average volume of 358,475. The business’s fifty day moving average price is $1.38 and its two-hundred day moving average price is $1.36. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $62.12 million, a P/E ratio of -6.05 and a beta of 0.82. MindWalk has a 52 week low of $0.99 and a 52 week high of $2.99.

Analyst Upgrades and Downgrades

HYFT has been the subject of several research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. Zacks Research cut shares of MindWalk from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 28th. Wall Street Zen raised shares of MindWalk from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating on shares of MindWalk in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, MindWalk has an average rating of “Hold” and an average price target of $5.00.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.